Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH.

Beenu ThakralL Jeffrey MedeirosParth DesaiPei LinC Cameron YinGuilin TangJoseph D KhouryShimin HuJie XuSanam LoghaviBei HuYasuhiro OkiShaoying Li

Published in: European journal of haematology (2017)

R-EPOCH therapy does not seem to impact the known poorer prognosis of patients with de novo CD5+ DLBCL, and CD5 expression was still an independent prognostic factor in R-EPOCH-treated patients with DLBCL.

Keyphrases

diffuse large b cell lymphoma
epstein barr virus
prognostic factors
poor prognosis
nk cells
binding protein
long non coding rna
mesenchymal stem cells
cell therapy